Collagen type II-induced arthritis (CIA) is generated in susceptible rodent strains by intradermal injections of homologous or heterologous native type II collagen in complete Freund's adjuvant. Symptoms of CIA are analogous to those of the human autoimmune disease, rheumatoid arthritis. CIA is a model system for T cell-mediated autoimmune disease. To study the T cell receptor (TCR) repertoire of bovine type II-specific T cells that may be involved in the pathogenesis of CIA in DBA/1Lac.J (H-2q) mice, 13 clonally distinct T cell hybridomas specific for bovine type II collagen have been established and the ot and/3 chains of their TCRs have been analyzed. These T cell hybridomas recognize epitopes that are shared by type II collagens from distinct species and not by type I collagens, and exhibit a highly restricted TCP,.-ot/3 repertoire. The ot chains of the TCRs employ three Vot gene subfamilies (Votll, Vot8, and Vot22) and four Jot gene segments (Jot42, Jot24, Jot37, and Jot32). The Vot22 is a newly identified subfamily consisting of approximately four to six members, and exhibits a high degree of polymorphism among four mouse strains of distinct Vot haplotypes. In addition, the B chains of the TCRs employ three V/3 gene subfamilies (V~8, VB1, and VB6), however the V38.2 gene segment is preferentially utilized (58.3%). In contrast, the JB gene segment usage is more heterogeneous. On the basis of the highly limited TCR-ot/3 repertoire of the TCRs of the panel of bovine type II-specific T cell hybrid clones, a significant reduction (60%) of the incidence of arthritis in DBA/1Lac.J mice is accomplished by the use of anti-V38.2 antibody therapy.
C
ollagen type II-induced arthritis (CIA) 1 in animals is an experimental animal model system of the human autoimmune disease, rheumatoid arthritis (1) (2) (3) . CIA is induced in susceptible rodents by intradermal injections of homologous or heterologous native collagen type II (1, 2) . In contrast, similar injections of other joint tissue proteins such as collagen type I and proteoglycans do not lead to arthritis. In addition, susceptibility to CIA in rodents is linked to MHC genes (4, 5) . Among the inbred mouse strains, only mice of the H-2q and H-2 r haplotypes generally acquire an inflammatory polyarthritis upon immunization with collagen type II in CFA (5). However, SWR (H-2q) and RIII (H-2 r) inbred mouse strains are resistant to CIA (6, 7) , suggesting that non-MHC genes are also crucial for the induction of the disease. 1 Abbreviations used in this paper: B.CII, bovine collagen type II; C.CII, chicken collagen type II; CIA, collagen type If-induced arthritis; EAE, experimental allergic encephalomyelitis; MBP, myelin basic protein; NOD, nonobese diabetic.
Previous studies indicate that CIA is associated with a high level of both cellular and humoral responses to collagen type II. However, the role of Abs and T lymphocytes in the pathogenesis of the disease is ill-defined. It has been reported that transfer of anti-collagen type II Abs to naive animals results in transient synovitis with a histopathologic picture different from that seen in CIA (8) . Hence, antibodies to collagen type II alone are not sufficient for the development of the prototypical lesions associated with arthritis. In contrast, adoptive transfer of collagen type II Abs and CD4 T cells isolated from mice immunized with denatured collagen type II, can together promote the development of dassical arthritis (9) . This finding clearly demonstrates the synergistic effect between humoral and cellular responses in initiating polyarthritis. The important role of CD4 T cells in the induction of arthritis is manifested indirectly by the in vivo administration of anti-MHC class II Abs, resulting in the inhibition of CIA (10) . Moreover, direct involvement of T cells has been illustrated by the resistance of athymic nude rats, and anti-CD4 treated mice to CIA (11, 12) .
The analysis of TCRs of myelin basic protein (MBP)-reac-tive T cells derived from the experimental allergic encephalomyelitis (EAE)-susceptible B10.PL mice revealed that the TCR-o~/3 repertoire is highly restricted, using only two Vol gene segments (Vo~2.3 and Vc~4.2) and two V3 gene segments (V~8.2 and V313) (13) . In addition, a similar finding has been obtained from T cell clones derived from PL/J mice and Lewis rats (14, 15) . Consequently, the prevention and reversal of EAE in B10.PL mice was accomplished using a combination of anti-VB8.2 and anti-V313 mAbs (16) . These surprising results have suggested that autoaggressive T cells in other autoimmune diseases may generally exhibit restricted TCR repertoires, and that anti-TCR therapies may prevent and/or cure autoimmune diseases. However, the notion that pathogenic T cells in autoimmune diseases exhibit limited TCR repertoires cannot be generalized to every autoimmune disease since molecular characterization of the TCRs used by islet-infiltrating T cells of nonobese diabetic (NOD) mice revealed that the usage of TCR V and J gene segments is not restricted as in the case of EAE (17, 18) . The question of whether or not the TCR repertoire of T cells involved in the induction of CIA is limited has been addressed indirectly by two different groups. The first group has found that DBA/1 mice treated with (a) anti-V38.1,8.2 mAb (KJ16) and (b) anti-V35.1,5.2 mAb (MR9.4), before injections of bovine collagen type II (B.CII) had a reduced incidence of arthritis, 28.6 and 50%o, respectively, as opposed to an 84.6% incidence in control mice (19) . This observation suggests that T cells involved in the pathogenesis ofpolyarthritis may exhibit a restricted use of TCR V3 chains (19) . The second study has utilized a PCR technique to examine TCR V3 gene usage in cells obtained from the joints as well as LNs of B10.Q mice injected with chicken collagen type II (C.CII) (20) . The authors observed that, whereas the joint T cells expressed VB2, V36, VB8.2, V/~9, VB10, and VB15 transcripts, the LN cells showed V36, V38.2, and VB9 transcripts. Although there are at least six different VB gene subfamilies expressed in the afflicted joints, and neither the specificity nor the clinical significance of the T cells expressing the above V~ gene elements is known, the authors claimed that there is restrictive usage of TCR V3 segments in CIA.
The present study aims at determining in more detail the TCR-c~/3 repertoire of the T cell response to B.CII that may play an important role in the induction of arthritis in DBA/1Lac.J (H-2q) mice immunized with B.CII. 13 clonally distinct T cell hybridomas specific for B.CII have been established. These T cell hybridomas exhibit a highly restricted TCR-oJ3 repertoire. Accordingly, we were able to ameliorate CIA disease in mice by the use ofTCR V38.2-specific Ab.
Materials and Methods
Mice. DBA/1LacJ, BALB/cJ, C57BL/6J, and SWR/J mice were purchased from The Jackson Laboratory (Bar Harbor, ME).
Establishment of RCIl-specific T Cell Hybridomas. Male DBA/ 1Lac.J mice were immunized intradermally with 100/zg native B.CII (Elastin Products Company Inc., Owensville, MO) in CFA. Inguinal and popliteal LNs from three to four mice were removed 10 d later, and a single cell suspension was made in a serum-free 388 medium (HL-1; Ventrex Laboratories, Portland, ME Southern Blot Analysis. Southern blot analysis was carried out as described previously (27) . The probe used to identify the Vc~22 gene subfamily was made from the PCR product obtained from the amplification of a cDNA clone containing the TCR c~ chain gene of the 57.7 T cell hybridoma using two primers derived from the Voe22.1 gene segment: the sequence of the 5' primer was 5' CCGAATTACTTCTGGTGGTAC 3' whereas the sequence of the 3' primer was 5' TGCTGCTGCACAGAAGTAGAT 3'.
A Limited T Cell Receptor Repertoire in Collagen-induced Arthritis PCR Amplification and Sequence Analysis. Total cellular RNA were isolated from the B.C II-8pecific T cell hybridomas (28) . Firststrand cDNA synthesis of TCR ce or 3 chain gene was performed using Ca primer (5' AGAGGGTGCTGTCCTGAGAC 3') or C3 primer (5' GCCAAGCACACGAGGGTAGCC 3'). The reverse transcription reaction was performed in a DNA thermal cycler (Perkin-Elmer Cetu8 Corp., Norwalk, CT). The synthesized firststrand cDNA containing TCR.-ce or -13 was then used as a template for the PCR amplification reaction. To amplify unknown Vc~ and V3 genes expressed by the T cell hybridomas, three 5' consensus Vce primers (5' VaA: 5' CTTCTGGTGGTACAGACA 3', 5' VceB: 5' TCCTTTTC'I'GGTATGTGCA 3', and 5' Vc~C: 5' AGCTGCAGTGGTTCCAACA 3'), and a single 5' consensus V3 primer (5' AR'GTACTGGTATCAGCAG 3') were designed from all known Vc~ and V3 gene segment sequences and used with the above Cc~ and C3 primers. After amplification, T4 polymerase was then added and incubated at 37~ for 10 min. The PCR-amplified TCR-c~ or -3 gene product was electrophoresed through 1.2% lowmelting agarose gel and the DNA corresponding to the predicted size was isolated. The purified fragment was phosphorylated with a polynucleotide kinase and cloned into a blunt-ended &phosphor-ylated M13mp8 vector. Recombinant M13 were isolated and DNA sequence analysis was performed using the chain termination method (Sequenase version 2.0 kit; U.S. Biochemical, Cleveland, OH).
Results

Characterization ofB, CII-specific T Cell Hybridomas. B.CII-
reactive T cell hybrids were generated from three separate fusions. 13 were subdoned by limiting dilution (0.3 cell/well) for this study and their TCR oL and 3 chain genes were subjected to sequence analysis. These T cell hybridomas were tested for their specificity against the B.CII, C.CII, and B.CI proteins. As shown in Fig. 1 , all hybrids responded to both B.CII and C.CII, but not to B.CI. The low response of hybridoma 92 is due to the frequent loss of chromosomes encoding its TCR c~/3 chains in culture. Attempts to isolate a 92 hybridoma subclone expressing a high level of TCRs by limiting dilution has failed. These results indicate that the TCRs of these T cell hybridomas recognize conserved epitopes that are shared by type II collagens from different species and not by type I coUagens. Hence, the T cell hybrids are protein type specific but not species specific.
Sequences of the TCR cr/~ Chain Genes.
To examine heterogeneity of the T cell response to B.CII in CIA autoimmune disease, the TCR-oJ3 genes of the 13 B.CII-specific T cell hybridomas were subjected to sequence analysis using a sensitive and rapid PCR technique. On the basis of conserved 5' DNA sequences present in all known Vo~ and VB gene segments, we designed 5' Vo~ and 5' VB oligonucleotide primers and used them with 3' constant region Co~ and and 3' constant region C3 primers, respectively, to amplify cDNA from B.CII-specific T cell clones expressing unknown TCR V region genes (see Materials and Methods). These T cell hybrids have been derived from different mice and three independent fusion experiments, and therefore, the T cell hybridomas are a representative panel of B.CII-specific T cell clones. T cell clones can be divided based on Vot gene segment usage into three groups (Fig. 2) . The first group employs (26) . Hence, the presence of both Va11.1 ~ and Vot11.1 b gene segments in the DBA/1Lac.J genome, unequivocally indicates that they are not two allelic forms of the same gene segment, but rather two different members of the Vot11 subfamily. Consequently, a new nomenclature is proposed for these two gene segments: Vcdl.1 and Vodl.4 to replace the old nomenclature, Vot11.1 a and Vcdl.1 b, respectively. As noted in Fig. 2 , two Jo~ gene segments (,Ja42 and Jor were used in this group. The Jot42 segment is a newly identified functional Joe (29) and is preferentially selected by the rearranged Va11.1, 11.4 gene segments (five of seven). In the second group, all three 389
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Ju 2 T cell clones share the same Vo~8.4 and Joe24 gene segments. The Vo~8.4 gene segment is a member of the Va8 subfamily which consists of ~o8-10 members (30) . Finally, the third group uses a new Vo~ gene segment, Vol22.1, which is distinct from the other 21 Vo~ subfamilies that have been previously described (Wang, K., J. L. Klotz, G. Kiser, G. Bristol, E. Lai, E. Gese, M. Kronenberg, and L. Hood, manuscript in preparation). A partial sequence of the Voe22.1 gene is given in Fig. 3 A. Genomic Southern blot analysis was performed to estimate the size of the newly identified Vo~22 gene subfamily and to study the RFLP pattern among four inbred mouse strains of distinct Vo~ haplotypes: BALB/c (Voea), C57BL/6 (Vab), SWR (Vo~c), and DBA/1 (Vc~ a) (26, 31) . The result indicates that the Vo~22 subfamily consists of approximately four to six members (Fig. 3 B) . In addition, the Va22 gene subfamily exhibits a high degree of polymorphism as indicated by the RFLP patterns generated using EcoRI and BamHI restriction enzymes (Fig. 3 B) .
As shown in Fig. 2 , the first group employs three V~ gene subfamilies, V31, V36, and V38. Two members of the V38 subfamily were used, V38.2 and V~8.3. However, the V38.2 gene segment was found to be preferentially utilized (four of seven). Furthermore, seven distinct J3 gene segments of the available 12 functional J3 gene segments were used by the TCRs of the B.CII-reactive T cell hybridomas. Thus, unlike the biased V38.2 gene segment usage in this group, the use of J3 gene segments is more heterogeneous. In the second group, the T cell hybrid clones share the same VB8.2 andJ31.2. Finally, the third group uses V31 and V38.2 gene segments and three distinct J3 gene segments.
vol-jot and vfl-Dfl-Jfl Junctional Regions. A comparison
of the nucleotide and predicted amino acid sequences of the TCR oe/3 chain junctional regions expressed by B.CII-specific T cell hybridomas (Fig. 2) reveals that there is a strong selection for highly conserved V~x-Jo~ junctional regions within each group. In contrast, VB-D3-J3 junctional regions are generally diverse (Fig. 2) . Another interesting observation is that several TCRs share an identical oe chain in association with different 3 chains, e.g., clones 105, B120 (Vc~ll.1/V38.2 and Vall.1/V31), clones 57.7, 278 (Vo122.1/V38.2 and Vo~22.1/V31), and clones 92, Bl12 (Vc~ll.1/VB8.2 and Voell.1/V38.3). This indicates the strong in vivo selection by the antigen for either a particular oe chain or a combination of both o~ and 3 chains. The predicted amino acid sequence is given above the nucleotide sequence using the single letter code. The nucleotide sequence data will appear in the EMBL, Genbank, and DDBJ Nucleotide Sequence Databases (accession number X67949). (B) Genomic DNA were obtained from livers of BALB/c, C57BL/6, DBA/1Lac.J, and SWR./J mice. "~10 #g of EcoRI or BamHI-digested DNA was electrophoresed through a 0.7% agarose gel, transferred to a zeta-probe membrane, hybridized with a labeled Vc~22.1 probe, and exposed to an x-ray film for 3 d at -80~ with an intensifying screen. Fig. 4 A. In addition, 44.22.1 mAb recognized the TCR VB6 chain expressed by the clone 136.4 (Fig. 4 B) . By contrast, neither F23.2 nor 44.22.1 recognized TCR B chains displayed by the clones H131, 278, and B120 (Fig. 4, C-E) . This is consistent with the DNA sequence data (Fig. 2) , indicating that the three clones express the TCR V~I chain gene. The Ab RRS-1 stained the T cell clones expressing the TCP,. Va11.4, but not the TCR Va11.1 (Fig.  4, F and G) . Finally, KTS0 and KT65 mAbs specific for the TCR Vow8 chain failed to recognize the TCR. Vo~8.4 chain that is employed by three distinct T cell clones (Figs. 2 and  4 H) . Therefore, neither anti-Vow11 nor anti-Vow8 mAbs can be used in our attempt to block CIA since both Abs failed to recognize the corresponding TCRs displayed by the majority of B.CII-reactive T cell hybrid clones. Therefore, the anti-VBS.2 and the anti-Vfl6 are the mAbs of choice for intervention experiments since neither anti-V~l nor appropriate antiVa mAbs are yet available. T cells reactive with the F23.2 mAb comprise 8-9% of T lymphocytes in the LNs of a normal DBA/1Lac.J mouse (Fig. 4/) . To examine the efficacy of in vivo depletion of T cells expressing TCR VBS.2, an intraperitoneal injection of 0.5 mg F23.2 Ab per mouse was found to be extremely effcient in eliminating virtually all TCR. V~8.2-bearing T cells in LNs after 3 d (Fig. 4J) . The first question addressed was whether CIA can be blocked in DBA/1Lac.J mice with anti-V~8.2 Ab treatment. Mice received anti-Vfl8.2 Ab treatment twice: initially, 3 d before the intradermal primary immunization with B.CII in CFA, and the second time before the intraperitoneal boost on day 21. As shown in Table 1 , only 6 of 20 mice treated with anti-VBS.2 Ab developed arthritis (30%), whereas 18 of 20 mice in the untreated group (90%), as well as 9 of 10 mice in the mouse IgG1 (MOPC21) treated group (90%) developed chronic polyarthritis.
Second, we were interested in examining whether mice treated with both anti-V~8.2 and anti-V~6 Abs would exhibit a reduced incidence of arthritis as compared with those pretreated with anti-V~8.2 Ab alone. Table 1 indicates that there is no significant difference between mice that received anti-VflS.2 Ab alone and those given anti-Vfl6 together with anti-V~8.2 Abs. Evidently, anti-VB8.2 Ab treatment alone is suffcient to reduce the incidence of arthritis by 60% in DBA/1Lac.J mice immunized with B.CII.
Discussion
CIA in mice is MHC class II restricted and a CD4 T cell-dependent autoimmune disease (10, 12) . CIA resembles human rheumatoid arthritis in many clinical, histological, and immunological respects. These remarkable similarities make CIA an ideal model system for study. The experiments described in this report endeavored to determine the TCR-a/~ repertoire in the CIA autoimmune disease model. 13 clonally distinct T cell hybridomas specific for B.CII have been established, and the cx and ~ chain gene usage of their TCILs have been determined.
The T cell hybridomas recognized conserved epitopes, present only in collagen type II molecules from different species, and exhibited a limited TCR-oJB repertoire. Although T cell clones displayed three TCR ~/chains (Vfl8, VBI, and Vfl6), the VflS.2 gene segment is preferentially employed by the B.CII-specific T cell hybrid clones (58%) (Fig. 2) . Unlike the Vfl gene segment usage, the Vfl-Dfl-Jfl junctional regions utilized are more heterogeneous (Fig. 2) . Therefore, the repeated usage of two Vfl gene segments (VB1, 25% and VBS.2, 58.3%), since both Vfl6 and Vf18.3 were used only once, strongly indicates that the TCR-B repertoire of the panel of the T cell hybridomas studied here is highly restricted. One plausible explanation for these highly restricted VB gene segments with diverse V~D~-J~junctional regions is that the amino acid residues of VB1 and V/~8.2 regions and not the J~/, D~, or N region residues are primarily responsible for the interaction with collagen peptide-MHC complexes. In addition, of the three Vc~ gene subfamilies used by the TCRs of B.CII-reactive T cell hybridomas (Vo~11, V~8, and Vc~22), the Vo~11 gene subfamily is preferentially utilized (54%). Based on the Vol gene segment usage, the TCR cr chains of the T cell clones are divided into three groups. Within each group, Vc~-Jc~ junctional regions are highly conserved. Considering the powerful diversification mechanisms available for the TCR ot/~ chain genes, it is therefore obvious from the repeated usage of a few Vo~ gene segments (Vo~11. The resistance of the SWR mouse strain of the susceptible MHC haplotype (H-2q) to CIA has been assigned either to its genomic deletion of 50% of the TCR. VB gene segments, indicating the lack of expressing crucial VB genes (32), or to the deficiency of the C5 complement component (33) . Our data demonstrating the effectiveness of anti-TCR V~8.2 Ab therapy in preventing CIA in DBA/1Lac.J mice, strongly suggest that the resistance of SWR mouse to arthritis may be due at least in part to the genomic deletion of the V~8.2 gene segment.
Akin to the EAE autoimmune disease model, CIA utilizes a highly restricted TCR-cff~ repertoire and affords an opportunity for testing a specific immune manipulation. In establishing successful treatment of EAE, several specific immune intervention tactics were applied to eliminate or inactivate autoaggressive T cell clones. Among these approaches are: (a) the vaccination of Lewis rats against EAE by the use of synthetic peptides derived from either the hypervariable regions II or III of the TCR V~/8.2 chain (34, 35); (b) the utilization of soluble class II MHC-MBP peptide complexes; prevention of EAE in SJL mice was accomplished by the intravenous injections of soluble complexes consisting of encephalitogenic peptide 91-103 of MBP and MHC class II (I-A s) protein (36) ; and (c) the prevention of EAE in B10.PL mice by the use of a combination of anti-VB8.2 and anti-VB13 mAbs to eliminate the pathogenic T cells (16) . Employing these therapeutic means towards CIA may prove to be successful. However, the first and second approaches are 393 Osman et al.
limited in their use because of required a priori knowledge. In the case of immunization with peptides derived from the TCR VB8.2, it is assumed that the host will elicit an immune response against that peptide, however this is not always the case since certain hosts may not be responsive to given peptides. As for using soluble MHC-peptide complexes, the identification of all different pathogenic T cell epitopes is a prerequisite. Since the anti-TCR Ab approach is not limited in the above respects, we believe that anti-TCR Ab therapy is an effective, therapeutic approach in preventing CIA as we have recently demonstrated in the case of EAE (16) . On the basis of the limited heterogeneity of the TCR c~/3 chains employed by the panel of T cell hybrid clones described here, examination of whether anti-TCR Ab therapy resuhs in preventing the development of chronic polyarthritis, as in the case of the EAE autoimmune disease model, was possible. From our findings, it is evident that the anti-V38.2 Ab treatment is significant in reducing the incidence of arthritis by 60% in DBA/1Lac.J mice immunized with B.CII, whereas the anti-V36 Ab treatment does not result in any significant reduction of the disease incidence. One possible explanation for the failure of anti-V/~6 treatment in reducing arthritis in mice, is that B.CII-specific V/~6-expressing T cells may not play a clinically significant role in the induction of arthritis in mice. Another possibility is that the anti-VB6 mAb which is a rat IgG2a mAb, may not be effective in eliminating all VB6-bearing T cells as compared with the effective anti-VB8.2 mAb (mouse IgG1). Furthermore, it is not dear why some mice developed arthritis in spite of anti-V/~8.2 treatment. One prospect is that these mice expand some other autoaggressive V3 TCR-bearing cells because of the presence of a microenvironmental factor such as a bacterium or a virus. According to our sequence data, potential candidates are those expressing TCR V31 chains. Unfortunately, anti-V31 Ab is not available, and hence, it is not possible to examine the above prospect. Nonetheless, attempts to raise this Ab and to characterize the TCRs of the pathogenic T cell subset in the anti-V38.2 treated mice are currently in progress.
In an attempt to address the issue that has been raised by Banerjee et al. (6) that certain TCR V3 genes such as those which are deleted in the SWR mouse strain (37) play an important role in the induction of arthritis, Goldschmidt et al. (39) studied the effect of anti-TCR Ab treatment on CIA. They reported that the in vivo administration of anti-VB8.1, 8.2 or anti-V36 Ab did not result in any significant alteration of CIA in DBA/1 mice immunized with rat collagen type II. In addition, their analysis of T cells obtained from Ab treated mice on day 21 revealed that 50% of V/~8.1, 8.2-expressing T cells reemerged (38) . Consequently, the efficiency of the Ab treatment in diminating V38.1,8.2-bearing T cells may account for the discrepancy between Goldschmidt group's and our findings. It is important to recall that in our study, mice received anti-V/38.2 Ab therapy twice; initially, 3 d before the primary immunization and the second time, on day 18. The rationale for this regimen is to ensure a very efficient depletion of VB8.2-expressing T ceils over a long period of time. Therefore, the successful inhibition of CIA in DBA/1 mice may hinge upon the efficacy of the Ab treatment in eliminating the autoaggressive V38.2-bearing T cells. A similar observation has been documented by Chiocchia et al. (19) .
In conclusion, analysis of the TCR oe/B chains of our panel of B.CII-specific T cell hybridomas has demonstrated that the TCR-od~ repertoire is limited towards the utilization of a few Vo~ and V3 gene segments. Furthermore, the anti-TCK therapy was found to be a very effective approach to significantly reduce the incidence of arthritis in DBA/1Lac.J mice. Nevertheless, a complete understanding of the molecular basis of the immune recognition in CIA depends fully upon the identification and characterization of different pathogenic collagen II peptides involved in the activation of the autoaggressive T cells. Thus, our panel of well-characterized T cell hybridomas is an extremely powerful tool to map and define the arthritogenic peptides involved in the disease induction. Currently, experiments designed to elute and sequence peptides bound in the MHC cleft using tandem mass spectrometry are in progress (39) . Moreover, full characterization of the CIA autoimmune disease model may provide a basis towards future therapeutic strategies for preventive medicine in humans.
